Merdury Biopharmaceutical

Merdury Biopharmaceutical Gross Margin

The Gross Margin of Merdury Biopharmaceutical (6932.TWO) as of Nov 17, 2026 is 84.30 %. In the previous year, Gross Margin was 57.31 % — a change of 47.10% (higher).

Gross Margin

84.30 %

YoY

47.10%

Last updated:

Gross Margin of Merdury Biopharmaceutical is 2024 84.30 % . Gross Margin of Merdury Biopharmaceutical was 2023 57.31 % . It decreases by 47.10% higher compared to the previous year.

Merdury Biopharmaceutical's gross margin stands at 84.3%, up from 43.7% several years earlier.

The Merdury Biopharmaceutical Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2022
43.73 TWD
Jan 1, 2023
57.31 TWD
Jan 1, 2024
84.30 TWD
The Merdury Biopharmaceutical Gross Margin history
YEARGross MarginYoY
84.30 %+47.10%
57.31 %+31.05%
43.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Merdury Biopharmaceutical Stock analysis

What does Merdury Biopharmaceutical do? Merdury Biopharmaceutical Corp develops and manufactures pharmaceutical products including Sildenafil, Metformin, Tadalafil, Zolpidem, angina drugs, migraine drugs, and multi-ingredient antihypertensive drugs. The company utilizes its StackDose platform to create controllable time-dissolving tablets for instant or sustained drug release. Products are primarily sold in Taiwan and the United States, targeting markets for drugs that do not meet special medical needs, difficult generics, and second-class new drugs. The company's revenue comes from the sale of these pharmaceutical products to customers in both regions. The firm's StackDose technology enables the development of specialized drug formulations that control the timing of drug effectiveness, differentiating its product range. This focus on innovative delivery systems supports sales in the pharmaceutical markets of Taiwan and the U.S., where demand exists for advanced generic and specialty medications. The company's product portfolio aligns with its strategic focus on non-special medical need drugs and second-class new drugs. Merdury Biopharmaceutical Corp targets healthcare providers and pharmacies in Taiwan and the United States as its primary customers. The company's self-developed StackDose platform allows for the creation of unique drug delivery systems that are sold under the company's own product lines. Sales of Sildenafil, Metformin, Tadalafil, and other key products form the core of the company's revenue streams. Merdury Biopharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merdury Biopharmaceutical stock

Gross Margin of Merdury Biopharmaceutical is 84.30 % in 2024.

Gross Margin of Merdury Biopharmaceutical changed from 57.31 % to 84.30 %, representing a 47.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Merdury Biopharmaceutical since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Merdury Biopharmaceutical with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Merdury Biopharmaceutical

All Key Metrics — Merdury Biopharmaceutical